Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
A legfontosabb adatok
- Ki végzi
- Vaxcyte, Inc.
- Hol
- Austin, Beaumont, Charlottesville, Chinle, Edmond, Gallup, Hendersonville, Hollywood, Jupiter, Kansas City, Lenexa, New Orleans, Newport News, Omaha, Phoenix, Port Saint Lucie, Rochester, Rockville, San Antonio, Shiprock, Southfield, Springfield, Stockbridge, Sugar Land, Sunrise, The Villages, Valparaiso, Waterbury, Whiteriver és Wilmington (Egyesült Államok)Mind a 30 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 3. fázis
- Résztvevők
- 752 fő vett részt
- Kezdés
- 2026. febr. 9.
- Befejezés
- 2026. okt. 25.
- A vizsgálat típusa
- Beavatkozással járó, 6 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- 31-valent pneumococcal conjugate vaccine
- PCV20
- A regiszteradat frissítve
- 2026. november 13.
Ki vehet részt
- Életkor
- 50 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female ≥50 years of age (inclusive) at the time of randomization into the study
- Previous receipt of a licensed pneumococcal vaccine or combination of licensed vaccines, with most recent vaccination ≥1 year prior to randomization; the exception is PCV21, which may have been received ≥6 months prior to randomization (confirmed)
- Able and willing to complete the informed consent process
- Available for clinical follow-up through the last study visit
- In good general health or with stable underlying chronic condition(s), as determined by medical history, oral temperature, physical examination, and clinical judgment of the Investigator (ongoing chronic conditions must be documented as stable per Investigator)
- Willing to have blood samples collected and used for research purposes
- Able to provide proof of identity to the satisfaction of the site personnel completing the enrollment process
- Female participants of childbearing potential, defined as premenopausal females capable of becoming pregnant, must have a negative urine pregnancy test immediately prior to randomization and agree to use acceptable contraception. Male subjects with partners of childbearing potential must agree to practice an acceptable contraception method
- Able to access and use a device connected to Wi-Fi or cellular network for completion of an electronic diary (eDiary)
Ki nem vehet részt
- Previous receipt of an investigational pneumococcal vaccine at any age
- Receipt of any investigational product within 30 days prior to Day 1, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study
- Receipt of any live vaccine within 30 days prior to Day 1, or receipt of any non-live (including inactivated) vaccine within 14 days prior to Day 1
- Body temperature >38.0°C (>100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescreened)
- History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis to any previous vaccination
- Receipt of blood or blood product (including polyclonal intravenous immunoglobulin) within 60 days prior to enrollment into the study
- Is currently receiving immunosuppressive or immune-modifying therapy, including systemic corticosteroids (this includes ≥3 months of prednisone equivalent from 5 to ≤10 mg/day and ≥2 weeks of prednisone equivalent >10 mg/day)
- Current diagnosis of human immunodeficiency virus, Hepatitis B, or Hepatitis C
- Has a known or suspected immunocompromising condition, including, but not limited to, leukemia, lymphoma, chronic renal failure, or congenital or acquired immunodeficiency
- Any medical, psychiatric, or social condition that in the judgment of the Investigator is a contraindication to protocol participation or impairs a subject's ability to give informed consent
- Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) resulting in clinically significant bruising or bleeding difficulties with IM injections or blood draws
- Previous invasive pneumococcal disease (IPD) or pneumococcal pneumonia (either confirmed or self-reported) at any age
- Received any part of a ≥14-day course of systemic corticosteroids (prednisone equivalent >10 mg/day) within 14 days of study vaccination; History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
- Individual who is pregnant, breastfeeding, or planning to become pregnant during study participation
- Employee of, or first-degree relative of, any person employed by the Sponsor, the contract research organization (CRO), the Investigator, site personnel, or site
Helyszínek itt: Egyesült Államok
- Tekton ResearchAustin, Egyesült Államok
- REX Clinical TrialsBeaumont, Egyesült Államok
- Alcanza (Charlottesville Medical Research)Charlottesville, Egyesült Államok
- Chinle Center for Indigenous HealthChinle, Egyesült Államok
- Tekton ResearchEdmond, Egyesült Államok
- Center of American Indian HealthGallup, Egyesült Államok
- DelRicht ResearchHendersonville, Egyesült Államok
- CenExel RCAHollywood, Egyesült Államok
- Eximia (Health Awareness)Jupiter, Egyesült Államok
- AMRKansas City, Egyesült Államok
- Johnson County Clin-Trials, LLCLenexa, Egyesült Államok
- DelRicht Clinical ResearchNew Orleans, Egyesült Államok
- Health Research of Hampton Roads, Inc.Newport News, Egyesült Államok
- Quality Clinical ResearchOmaha, Egyesült Államok
- Avacare (CCT Research)Phoenix, Egyesült Államok
- Eximia (Health Awareness)Port Saint Lucie, Egyesült Államok
- Rochester Clinical Research, IncRochester, Egyesült Államok
- Velocity (Meridian Clinical Research)Rockville, Egyesült Államok
- Flourish ResearchSan Antonio, Egyesült Államok
- Shiprock Center for Indigenous HealthShiprock, Egyesült Államok
- DM Clinical Research - DetroitSouthfield, Egyesült Államok
- Delricht Research - Command Family MedicineSpringfield, Egyesült Államok
- DelRicht Clinical ResearchStockbridge, Egyesült Államok
- DM Clinical ResearchSugar Land, Egyesült Államok
- Precision Clinical ResearchSunrise, Egyesült Államok
- The VillagesThe Villages, Egyesült Államok
- Velocity Clinical_ValparaisoValparaiso, Egyesült Államok
- Chase Medical ResearchWaterbury, Egyesült Államok
- Whiteriver Center for Indigenous HealthWhiteriver, Egyesült Államok
- Headlands (Trial Management Associates)Wilmington, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
A vizsgálat 6 csoportja
- Cohort 1 (VAX-31): Prior PPSV23A vizsgált kezelés
Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1
Kezelés: 31-valent pneumococcal conjugate vaccine
- Cohort 1 (PCV20): Prior PPSV23Már használt kezelés, összehasonlításként
Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1
Kezelés: PCV20
- Cohort 2 (VAX-31): Prior PCV20A vizsgált kezelés
Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1
Kezelés: 31-valent pneumococcal conjugate vaccine
- Cohort 2 (PCV20): Prior PCV20Már használt kezelés, összehasonlításként
Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1
Kezelés: PCV20
- Cohort 3 (VAX-31): Other prior licensed pneumococcal vaccine or combinationA vizsgált kezelés
Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1
Kezelés: 31-valent pneumococcal conjugate vaccine
- Cohort 3 (PCV20): Other prior licensed pneumococcal vaccine or combinationMár használt kezelés, összehasonlításként
Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1
Kezelés: PCV20
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Prior Pneumococcal Vaccination
- A regiszteradat frissítve
- 2026. november 13.